Bora follows the guidance of the Access to Medicine Index (ATMI), committed to improving drug research and development, accessibility, and affordability. The Company pledges to ensure stable drug supply at reasonable prices to benefit more patients and support the sustainable development of global healthcare systems. We currently do not engage in the development of proprietary new chemical entities (NCEs). Its existing product portfolio primarily consists of FDA 505(b)(2) modified drugs and generic drugs. The pricing of such products is heavily influenced by national regulatory pricing systems, healthcare reimbursement policies, and market competition, leaving the company with relatively limited flexibility in pricing decisions.
Moreover, the current product range does not include treatments for hepatitis C or other major infectious diseases that are among the most urgent healthcare needs in developing countries. As a result, Bora’s access-to-medicine strategy is centered on ensuring stable supply and fair pricing of its existing products, rather than developing new drugs targeting diseases prevalent in the developing world.
Promise of Support™ Program
Bora’s pharma sales operations are mainly under the Upsher-Smith brand in the U.S., who has long provided dedicated services to rare disease groups through the Promise of Support™ Program, ensuring comprehensive assistance for patients, caregivers, and healthcare providers throughout the treatment process.
Suffering from rare diseases often brings significant financial, emotional, physical, and psychological challenges to patients and their families, and accessing necessary prescription treatments may further increase these burdens. For the rare disease branded drugs we provide, Upsher-Smith is committed to continuously learning the specific needs of each disease and treatment plan, and fully providing services and support to help patients reduce difficulties and obstacles during the treatment process.
Currently, the program covers 3 products:
- Vigadrone® powder for oral solution
- Vigadrone® tablets
- TORPENZ™ tablets
Drug Donation Project
Guided by the mission “Contributing to Better Health All Over the World,” Bora Pharmaceuticals embraces its social responsibility by supporting healthcare access in underserved communities.
By proactively offering medicines to populations with economic or geographic barriers, Bora aims to promote health equity. Upsher-Smith donated over USD $162,858 and USD$ $162,858 in 2023and 2024, respectively.
Responsible Pricing
Bora adheres to the principles of fairness and affordability, implementing a tiered pricing strategy based on the World Health Organization’s National Drug Pricing Policy Guidelines. Pricing considers market characteristics of each country, integrating factors such as GDP and local income levels to improve patient access and affordability. At the same time, we also incorporate local distributors and insurance reimbursement mechanisms to ensure reasonable drug pricing.